Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

Old API Wind-down Ltd - Ordinary Shares > Toprol-XL Contract Renewal
View:
Post by snootchybootchy on Apr 11, 2017 6:57pm

Toprol-XL Contract Renewal

Aralez's contract with the Department of Veterans Affairs to supply Toprol-XL have been renewed for at least another year.  This renewal confirms cashflow as management ramps up sales for Zontivity and Yosprala.  8-K filing can be found here.  Look for a news release tomorrow morning before market open.
Comment by biggerr on Apr 11, 2017 9:12pm
it says not just the Vet Affairs but also some other gov't departments. A secure income for ARZ because gov't seldom cancels a contract unless there is a serious problem and Trump promised to improve the treatment of veterans
Comment by kuatolives on Apr 12, 2017 10:55am
Even if you think zontivity and Toprol have a significant future, do you really want to be betting on a management team that screwed up so badly with Yosprala? Both Adams and his execs allowed themselves to believe in something that simply wasn't true. There are good management teams out there. Seek them out and yee shall make $$.
Comment by biggerr on Apr 12, 2017 1:13pm
they're supposed to launch Zontivity this month so let's see how it goes, PAR-1 based anticoagulants like Zon are new on the market and they need time to establish themselves. Also Toprol being used by the Vet Affairs is like a free publicity for the drug
Comment by biggerr on Apr 12, 2017 3:45pm
speaking of blood, it's a real bloodbath in the last 2 days, down by almost 20%, we could need some vitamin K here to stop the bleeding, hah
Comment by biggerr on Apr 12, 2017 4:35pm
the way ARZ is collapsing in the last 2 days raises the question if they are expecting a BK 
Comment by GoldenDilemma on Apr 12, 2017 7:03pm
Did you guys just start looking at ARLZ price performance or something in the past week? This has always been the case. It didn't just go from $12.50 to $1.55 overnight. 
Comment by GoldenDilemma on Apr 12, 2017 7:05pm
To clarify: downward pressure on the price has always been the case because of the short bias against this company. Then when shorts cover and price goes up 15% or something, everyone long has the psychological relief thinking it's over... and then new bag holders are made because they buy into shorts covering... and then the next day it's re-shorted.
Comment by biggerr on Apr 12, 2017 8:16pm
at least it's very close to the bottom now, it's not like buying it at $7 and going all the way down to $2 for gad sake 
Comment by GoldenDilemma on Apr 13, 2017 8:00am
Oh yeah? You sure about that bottom? Any sort of technical assessment to a price should have some sound reasoning. There is no objective reasoning as to ARLZ being at a bottom. Give it one more month before Q1 readouts. Remember: Yosprala sold through Q1 2017. ARLZ just cut the Yosprala sales force after Q1........ you think that's a bullish signal? Furthermore, if they want to completely ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities